| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,100 | 6,400 | 14:54 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 22,200 | 30 | |||
| 20,000 | 83 | |||
| 19,600 | 2 | |||
| 16,000 | 532 | |||
| 15,000 | 15 | |||
| 6,400 | 807 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 807 | 6,100 | |||
| 50 | 6,000 | |||
| 450 | 5,300 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.368 | 0,620 | 1.469 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | 4basebio strengthens commercial leadership, promoting Christine Wolosin to Chief Commercial Officer | 143 | GlobeNewswire (Europe) | Seasoned biotechnology commercial leader will drive global growth strategy Commercial team further bolstered by promotions of James Vang and Jennifer Gelman to VP, Business Development and VP, Marketing... ► Artikel lesen | |
| Di | 4basebio Plc - Appointment of CCO | 195 | PR Newswire | 4basebio Plc - Appointment of CCO
PR Newswire
LONDON, United Kingdom, March 03
THIS... ► Artikel lesen | |
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 16.02. | 4BASEBIO PLC: Director Dealing | 8 | Cision News | ||
| 16.02. | 4basebio Plc - Director Dealing | 272 | PR Newswire | 4basebio Plc - Director Dealing
PR Newswire
LONDON, United Kingdom, February 16
16 February... ► Artikel lesen | |
| 11.02. | 4basebio directors acquire shares in market transactions | 12 | Investing.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 11:02 | BioNTech-Konkurrent Moderna: Satter Kurssprung - jetzt noch einsteigen? | Der Aktionär | Die Aktie von Moderna hat zuletzt erneut kräftigen Rückenwind erhalten. Die Korrektur seit Ende Januar wurde damit nicht nur vollständig wieder ausgeglichen, das Papier konnte sogar auf ein neues Jahreshoch... ► Artikel lesen | |
| 13:06 | Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer | GlobeNewswire (Europe) | Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital... ► Artikel lesen | |
| 13:06 | Erasca, Inc.: Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat | GlobeNewswire (Europe) | ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO... ► Artikel lesen | |
| 13:06 | Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates | GlobeNewswire (Europe) | Achieved Q4 2025 PEMGARDA (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.7... ► Artikel lesen | |
| 13:06 | Bioventus, Inc.: Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results | GlobeNewswire (Europe) | Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0%Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year periodNon-GAAP... ► Artikel lesen |